64224-21-1 | 4-Methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
10mg	98%	in stock	$9.00	$6.00
50mg	98%	in stock	$20.00	$14.00
100mg	98%	in stock	$30.00	$21.00

Description

• Catalog Number: AI54302
• Chemical Name: 4-Methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
• CAS Number: 64224-21-1
• Molecular Formula: C8H6N2S3
• Molecular Weight: 226.3416
• MDL Number: MFCD00868499
• SMILES: S=c1ssc(c1C)c1cnccn1

Computed Properties

• Complexity: 262
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 13
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 1
• XLogP3: 1.1

Literature

• Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20171201

• Keap1-Independent Regulation of Nrf2 Activity by Protein Acetylation and a BET Bromodomain Protein.

  PLoS genetics 20160501

• Nrf2 activators as potential modulators of injury in human kidney cells.

  Toxicology reports 20160101

• Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.

  PloS one 20150101

• Multi-layer polymeric implants for sustained release of chemopreventives.

  Cancer letters 20121229

• Dietary modulation of the biotransformation and genotoxicity of aflatoxin B(1).

  Toxicology 20120928

• Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120701

• Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120601

• Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.

  Molecules (Basel, Switzerland) 20120315

• Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction.

  Carcinogenesis 20120301

• Tumor angiogenesis as a target for dietary cancer prevention.

  Journal of oncology 20120101

• Cigarette-Smoke-Induced Dysregulation of MicroRNA Expression and Its Role in Lung Carcinogenesis.

  Pulmonary medicine 20120101

• Induction of phase 2 antioxidant enzymes by broccoli sulforaphane: perspectives in maintaining the antioxidant activity of vitamins a, C, and e.

  Frontiers in genetics 20120101

• Cigarette smoke exposure-associated alterations to non-coding RNA.

  Frontiers in genetics 20120101

• A versatile ΦC31 based reporter system for measuring AP-1 and Nrf2 signaling in Drosophila and in tissue culture.

  PloS one 20120101

• Mechanism of chemical activation of Nrf2.

  PloS one 20120101

• Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11β-HSD1-mediated glucocorticoid activation in hepatic cells.

  PloS one 20120101

• Alternative strategy for Alzheimer's disease: stress response triggers.

  International journal of Alzheimer's disease 20120101

• Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats.

  Oxidative medicine and cellular longevity 20120101

• Quantification of oltipraz using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in rat plasma.

  Journal of pharmaceutical and biomedical analysis 20111101

• Antioxidative and chemopreventive properties of Vernonia amygdalina and Garcinia biflavonoid.

  International journal of environmental research and public health 20110601

• Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial.

  The Journal of pharmacy and pharmacology 20110501

• Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents.

  Drug metabolism reviews 20110501

• Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice.

  Diabetologia 20110401

• 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase.

  PloS one 20110101

• Protective effect of canolol from oxidative stress-induced cell damage in ARPE-19 cells via an ERK mediated antioxidative pathway.

  Molecular vision 20110101

• Apoptosis modulation as a promising target for treatment of systemic sclerosis.

  International journal of rheumatology 20110101

• Pathobiology and chemoprevention of bladder cancer.

  Journal of oncology 20110101

• Chemopreventive effect of cactus Opuntia ficus indica on oxidative stress and genotoxicity of aflatoxin B1.

  Nutrition & metabolism 20110101

• Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice.

  PloS one 20110101

• Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound.

  PloS one 20110101

• Pharmacokinetics of dl-praeruptorin A after single-dose intravenous administration to rats with liver cirrhosis.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

  Archives of toxicology 20101101

• Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.

  Clinical pharmacology and therapeutics 20100901

• Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.

  Bioorganic & medicinal chemistry 20100815

• Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening.

  PLoS neglected tropical diseases 20100801

• Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression.

  American journal of physiology. Gastrointestinal and liver physiology 20100701

• Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice.

  The Journal of pharmacology and experimental therapeutics 20100401

• Radioprotectors and mitigators of radiation-induced normal tissue injury.

  The oncologist 20100401

• Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes.

  Toxicology in vitro : an international journal published in association with BIBRA 20100301

• Quantitative morphometry of respiratory tract epithelial cells as a tool for testing chemopreventive agent efficacy.

  Anticancer research 20100301

• Antioxidant and mitochondrial protective effects of oxidized metabolites of oltipraz.

  Expert opinion on drug metabolism & toxicology 20100201

• Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs.

  Cancer prevention research (Philadelphia, Pa.) 20100101

• Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene.

  BMC cancer 20100101

• Fresh raspberry phytochemical extract inhibits hepatic lesion in a Wistar rat model.

  Nutrition & metabolism 20100101

• Effects of tert-butylhydroquinone on intestinal inflammatory response and apoptosis following traumatic brain injury in mice.

  Mediators of inflammation 20100101

• Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression.

  Hepatology (Baltimore, Md.) 20091101

• Therapeutic potential of dithiolethiones for hepatic diseases.

  Pharmacology & therapeutics 20091001

• Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect.

  Molecular cancer therapeutics 20091001

• Hydrogen peroxide is a second messenger in phase 2 enzyme induction by cancer chemopreventive dithiolethiones.

  Chemical research in toxicology 20090817

• Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.

  Journal of the Egyptian Society of Parasitology 20090801

• Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice.

  Toxicology letters 20090710

• Oxidized metabolites of oltipraz exert cytoprotective effects against arachidonic acid through AMP-activated protein kinase-dependent cellular antioxidant effect and mitochondrial protection.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.

  Hepatology (Baltimore, Md.) 20090601

• Inhibition of colon carcinogenesis by post-initiation induction of NQO1 in Sprague-Dawley rats.

  Oncology reports 20090601

• Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat.

  Toxicological sciences : an official journal of the Society of Toxicology 20090501

• Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling.

  Toxicological sciences : an official journal of the Society of Toxicology 20090401

• This month in APR.

  Archives of pharmacal research 20090401

• Oltipraz promotion of liver regeneration after partial hepatectomy: The role of PI3-kinase-dependent C/EBPbeta and cyclin E regulation.

  Archives of pharmacal research 20090401

• Comparison of citrus coumarins on carcinogen-detoxifying enzymes in Nrf2 knockout mice.

  Toxicology letters 20090328

• Chemical genomics of cancer chemopreventive dithiolethiones.

  Carcinogenesis 20090301

• Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.

  British journal of pharmacology 20090301

• Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20090201

• Role of hepatitis B virus X repression of C/EBPbeta activity in the down-regulation of glutathione S-transferase A2 gene: implications in other phase II detoxifying enzyme expression.

  Xenobiotica; the fate of foreign compounds in biological systems 20090201

• Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners.

  Molecular pharmacology 20090101

• Pharmacokinetic interaction between oltipraz and silymarin in rats.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20090101

• LAS0811: from combinatorial chemistry to activation of antioxidant response element.

  Journal of biomedicine & biotechnology 20090101

• Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.

  PloS one 20090101

• Unexpected aflatoxin exposure in a woman in northern Italy: a case report.

  Cases journal 20090101

• Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.

  Archives of toxicology 20081201

• Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers.

  Toxicological sciences : an official journal of the Society of Toxicology 20081201

• Dithiolethiones for cancer chemoprevention: where do we stand?

  Molecular cancer therapeutics 20081101

• Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response.

  Environmental health perspectives 20080901

• The Nrf2 activator oltipraz also activates the constitutive androstane receptor.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• A Bayesian approach estimating treatment effects on biomarkers containing zeros with detection limits.

  Statistics in medicine 20080615

• Abrogation of hyperosmotic impairment of insulin signaling by a novel class of 1,2-dithiole-3-thiones through the inhibition of S6K1 activation.

  Molecular pharmacology 20080501

• Minimal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis.

  Toxicological sciences : an official journal of the Society of Toxicology 20080301

• Dietary berries and ellagic acid prevent oxidative DNA damage and modulate expression of DNA repair genes.

  International journal of molecular sciences 20080301

• Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice.

  Toxicological sciences : an official journal of the Society of Toxicology 20080101

• Induction of drug metabolism enzymes and transporters by oltipraz in rats.

  Journal of biochemical and molecular toxicology 20080101

• Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats.

  Journal of biochemical and molecular toxicology 20080101

• A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer Biology.

  PPAR research 20080101

• Strategies for prostate cancer prevention: Review of the literature.

  Indian journal of urology : IJU : journal of the Urological Society of India 20080101

• Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration.

  Journal of inflammation research 20080101

• Induction of Nrf2-regulated genes by 3H-1, 2-dithiole-3-thione through the ERK signaling pathway in murine keratinocytes.

  European journal of pharmacology 20071222

• Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?

  Drug metabolism and disposition: the biological fate of chemicals 20071201

• Pharmacokinetic interaction between oltipraz and omeprazole in rats: Competitive inhibition of metabolism of oltipraz by omeprazole via CYP1A1 and 3A2, and of omeprazole by oltipraz via CYP1A1/2, 2D1/2, and 3A1/2.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20071201

• Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.

  Hepatology (Baltimore, Md.) 20071101

• Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention.

  Free radical biology & medicine 20071001

• Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway.

  Hepatology (Baltimore, Md.) 20070901

• Keap1 eye on the target: chemoprevention of liver cancer.

  Acta pharmacologica Sinica 20070901

• Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target.

  PLoS medicine 20070601

• Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines.

  Carcinogenesis 20070201

• Oltipraz may be useful in the prevention or treatment of Alzheimer's disease.

  Medical hypotheses 20070101

• Bench-to-bedside review: High-mobility group box 1 and critical illness.

  Critical care (London, England) 20070101

• Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets.

  Current cancer drug targets 20061201

• Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries.

  Environmental health perspectives 20061201

• cis-Terpenones as an effective chemopreventive agent against aflatoxin B1-induced cytotoxicity and TCDD-induced P450 1A/B activity in HepG2 cells.

  Chemical research in toxicology 20061101

• The induction of CYP1A1 by oltipraz is mediated through calcium-dependent-calpain.

  Toxicology letters 20061010

• A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.

  Contemporary clinical trials 20061001

• Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20061001

• Heme oxygenase-1 as a potential therapeutic target for hepatoprotection.

  Journal of biochemistry and molecular biology 20060930

• Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers.

  Free radical biology & medicine 20060915

• Inhibition of TGFbeta1-mediated PAI-1 induction by oltipraz through selective interruption of Smad 3 activation.

  Cytokine 20060901

• Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits.

  Statistics in medicine 20060815

• The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model.

  Carcinogenesis 20060801

• Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction.

  Drug metabolism and disposition: the biological fate of chemicals 20060801

• Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats.

  Journal of pharmaceutical sciences 20060501

• Pharmacokinetics and therapeutic effects of oltipraz after consecutive or intermittent oral administration in rats with liver cirrhosis induced by dimethylnitrosamine.

  Journal of pharmaceutical sciences 20060501

• Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin.

  Life sciences 20060411

• Early loss of Fhit in the respiratory tract of rodents exposed to environmental cigarette smoke.

  Cancer research 20060401

• Structure-activity relationships in the induction of Phase II enzymes by derivatives of 3H-1,2-dithiole-3-thione in rats.

  Chemico-biological interactions 20060325

• Effect of selenium-containing compounds on hepatic chemoprotective enzymes in mice.

  Toxicology 20060315

• The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 264.7 cells.

  The Journal of pharmacology and experimental therapeutics 20060301

• Antioxidant agents transiently inhibit aneuploidy progression in Li-Fraumeni cell strains.

  Molecular carcinogenesis 20060301

• Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

  Cancer research 20060215

• Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation.

  Molecular pharmacology 20060101

• Post-initiation chlorophyllin exposure does not modulate aflatoxin-induced foci in the liver and colon of rats.

  Journal of carcinogenesis 20060101

• Modest induction of phase 2 enzyme activity in the F-344 rat prostate.

  BMC cancer 20060101

• Cyanobacterial lipopolysaccharides and human health - a review.

  Environmental health : a global access science source 20060101

• Induction of antioxidant genes in the brain as a therapeutic target in bipolar disorder: potential role of oltipraz.

  Medical hypotheses 20060101

• Pretreatment of human epidermal keratinocytes with D,L-sulforaphane protects against sulfur mustard cytotoxicity.

  Cutaneous and ocular toxicology 20060101

• Modulation of multigene expression and proteome profiles by chemopreventive agents.

  Mutation research 20051211

• Modulation of apoptosis by cancer chemopreventive agents.

  Mutation research 20051211

• Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004.

  Environmental health perspectives 20051201

• Oltipraz-induced phase 2 enzyme response conserved in cells lacking mitochondrial DNA.

  Biochemical and biophysical research communications 20051111

• Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists.

  Carcinogenesis 20051001

• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  Current drug metabolism 20051001

• Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways.

  Drug metabolism and disposition: the biological fate of chemicals 20050901

• Enhanced CCAAT/enhancer-binding protein beta-liver-enriched inhibitory protein production by Oltipraz, which accompanies CUG repeat-binding protein-1 (CUGBP1) RNA-binding protein activation, leads to inhibition of preadipocyte differentiation.

  Molecular pharmacology 20050901

• Induction of phase-1 metabolizing enzymes by oltipraz, flavone and indole-3-carbinol enhance the formation and transport of benzo[a]pyrene sulfate conjugates in intestinal Caco-2 cells.

  Toxicology letters 20050814

• Assessing the effect of interventions in the context of mixture distributions with detection limits.

  Statistics in medicine 20050715

• Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver.

  Drug metabolism and disposition: the biological fate of chemicals 20050701

• Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition.

  Journal of pharmaceutical sciences 20050701

• Nrf2 as a novel molecular target for chemoprevention.

  Cancer letters 20050628

• Glutathione-mediated formation of oxygen free radicals by the major metabolite of oltipraz.

  Chemical research in toxicology 20050601

• Hepatic and intestinal first-pass effects of oltipraz in rats.

  Biopharmaceutics & drug disposition 20050501

• Glucocorticoid receptor (GR)-associated SMRT binding to C/EBPbeta TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression.

  Molecular and cellular biology 20050501

• Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.

  Biopharmaceutics & drug disposition 20050401

• Safety and efficacy of weekly oral oltipraz in chronic smokers.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20050401

• Effect of enzyme inducers and inhibitors on the pharmacokinetics of oltipraz in rats.

  The Journal of pharmacy and pharmacology 20050401

• Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours.

  Biopharmaceutics & drug disposition 20050301

• Cancer chemopreventive oltipraz generates superoxide anion radical.

  Archives of biochemistry and biophysics 20050301

• QSAR studies on 1,2-dithiole-3-thiones: modeling of lipophilicity, quinone reductase specific activity, and production of growth hormone.

  Bioorganic & medicinal chemistry letters 20050215

• Oltipraz regulates different categories of genes relevant to chemoprevention in human hepatocytes.

  Carcinogenesis 20050201

• Oltipraz, 3H-1,2-dithiole-3-thione, and sulforaphane induce overlapping and protective antioxidant responses in murine microglial cells.

  Toxicology letters 20041128

• Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas.

  Gastroenterology 20041101

• Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo.

  British journal of cancer 20041018

• Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.

  Cancer research 20040915

• Effects of acute renal failure on the pharmacokinetics of oltipraz in rats.

  Journal of pharmaceutical sciences 20040901

• Ceramide, an apoptotic rheostat, inhibits CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 activation: the role in glutathione S-transferase A2 gene repression.

  Drug metabolism and disposition: the biological fate of chemicals 20040901

• NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling.

  The Journal of biological chemistry 20040618

• Ceramide negatively regulates glutathione S-transferase gene transactivation via repression of hepatic nuclear factor-1 that is degraded by the ubiquitin proteasome system.

  Molecular pharmacology 20040601

• Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.

  European journal of cancer (Oxford, England : 1990) 20040601

• Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine.

  International journal of pharmaceutics 20040504

• Oltipraz inhibits inducible nitric oxide synthase in vitro and inhibits nitric oxide production in activated microglial cells.

  Archives of biochemistry and biophysics 20040415

• Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action.

  Breast cancer research : BCR 20040101

• In vitro effect of low concentrations of oltipraz on the antioxidant defence of mouse hepatocytes and Schistosoma mansoni worms.

  British journal of biomedical science 20040101

• Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases.

  Anticancer research 20040101

• Pretreatment of human epidermal keratinocytes in vitro with ethacrynic Acid reduces sulfur mustard cytotoxicity.

  Toxicology mechanisms and methods 20040101

• Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz.

  Carcinogenesis 20031201

• Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activation.

  The Journal of biological chemistry 20031107

• Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor.

  Drug metabolism and disposition: the biological fate of chemicals 20031101

• Phase 2 enzyme induction by the major metabolite of oltipraz.

  Chemical research in toxicology 20031101

• Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20030901

• Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats.

  The Journal of pharmacy and pharmacology 20030901

• Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element.

  Molecular pharmacology 20030801

• Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention.

  Biochemical pharmacology 20030701

• Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20030601

• Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice.

  Carcinogenesis 20030301

• [Development of bladder cancer chemoprevention].

  Wei sheng yan jiu = Journal of hygiene research 20030301

• Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones.

  The Journal of biological chemistry 20030124

• Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: evidence for a contribution of the Aryl hydrocarbon receptor pathway.

  Molecular pharmacology 20030101

• Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz.

  Journal of the National Cancer Institute 20030101

• Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis.

  Mutation research 20030101

• Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review.

  Journal of toxicology. Clinical toxicology 20030101

• In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells.

  Oncology reports 20030101

• Thiolytic chemistry of alternative precursors to the major metabolite of the cancer chemopreventive oltipraz.

  The Journal of organic chemistry 20021227

• Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021201

• Prevention of liver cancer.

  Current oncology reports 20021101

• Protection of retinal pigment epithelial cells from oxidative damage by oltipraz, a cancer chemopreventive agent.

  Investigative ophthalmology & visual science 20021101

• The anti-fibrogenic effect of a pharmaceutical composition of [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB).

  Archives of pharmacal research 20021001

• Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz.

  Molecular cancer therapeutics 20021001

• Strategies for chemoprevention of liver cancer.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20020801

• Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent.

  The Journal of biological chemistry 20020705

• Tissue distribution and chemical induction of multiple drug resistance genes in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20020701

• Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• Oltipraz protects the passive smoke induced changes in renal glyoxalase system of rats.

  Molecular and cellular biochemistry 20020401

• Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases.

  Drug metabolism and disposition: the biological fate of chemicals 20020301

• Investigations on the effects of oltipraz on the nucleotide excision repair in the liver.

  Biochemical pharmacology 20020215

• Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression.

  Chemico-biological interactions 20020122

• The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• Enhancing effects of oltipraz on the development of spontaneous hepatic lesions in LEC rats.

  Toxicologic pathology 20020101

• The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds.

  Cell biology and toxicology 20020101

• Cell-based studies reveal differences in glutathione S-transferase induction between oltipraz and tert-butylhydroquinone.

  Journal of biochemical and molecular toxicology 20020101

• The glutathione system in alkylator resistance.

  Cancer treatment and research 20020101

• Regulation of biliary drug efflux pump expression by hormones and xenobiotics.

  Toxicology 20011005

• Multiple points of intervention in the prevention of cancer and other mutation-related diseases.

  Mutation research 20010901

• Effect of chemopreventive agents on DNA adduction induced by the potent mammary carcinogen dibenzo[a,l]pyrene in the human breast cells MCF-7.

  Mutation research 20010901

• Role of phase 2 enzyme induction in chemoprotection by dithiolethiones.

  Mutation research 20010901

• A review of cancer chemopreventive agents.

  Current medicinal chemistry 20010901

• Kinetic constraints for the thiolysis of 4-methyl-5-(pyrazin-2-yl)-1,2-dithiole-3-thione (oltipraz) and related dithiole-3-thiones in aqueous solution.

  Chemical research in toxicology 20010801

• Formation of DNA adducts in the aorta of smoke-exposed rats, and modulation by chemopreventive agents.

  Mutation research 20010725

• An alternative promoter contributes to tissue- and inducer-specific expression of the rat UDP-glucuronosyltransferase 1A6 gene.

  Toxicology and applied pharmacology 20010701

• Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20010701

• Liquid chromatography electrospray-mass spectrometry of urinary aflatoxin biomarkers: characterization and application to dosimetry and chemoprevention in rats.

  Chemical research in toxicology 20010701

• In vivo inhibition of human CYP1A2 activity by oltipraz.

  Cancer chemotherapy and pharmacology 20010601

• The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes.

  Cancer research 20010415

• Modulation of biomarkers by chemopreventive agents in smoke-exposed rats.

  Cancer research 20010315

• Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats.

  Carcinogenesis 20010301

• Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20010301

• Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20010301

• Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione.

  Molecular medicine (Cambridge, Mass.) 20010201

• Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.

  Journal of the National Cancer Institute 20010103

• 1,2-dithiole-3-thione and its structural analogue oltipraz are potent inhibitors of dibenz.

  International journal of cancer 20010101

• Differential effects of oltipraz on CYP1A and CYP2B in rat lung.

  Carcinogenesis 20010101

• Chronic dosing of oltipraz in people at increased risk for colorectal cancer.

  Cancer detection and prevention 20010101

• Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenesis: implications for human biotransformation enzyme polymorphisms.

  Advances in experimental medicine and biology 20010101

• Comparative tissue-specific toxicities of 20 cancer preventive agents using cultured cells from 8 different normal human epithelia.

  In vitro & molecular toxicology 20010101

• Determination of a chemopreventive agent, Oltipraz, in rat plasma and urine by high-performance liquid chromatography.

  Research communications in molecular pathology and pharmacology 20010101

• Stability, blood partition and protein binding of an antifibrotic agent, oltipraz.

  Research communications in molecular pathology and pharmacology 20010101

• Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane.

  Chemical research in toxicology 20000401

• Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data.

  Anticancer research 20000101

• Role of glutamate 144 and glutamate 164 in the catalytic mechanism of enoyl-CoA hydratase.

  Biochemistry 19990720

• Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein.

  Carcinogenesis 19981201

• Increased bioactivation of dihaloalkanes in rat liver due to induction of class theta glutathione S-transferase T1-1.

  The Biochemical journal 19981101

• Effects of dietary anticarcinogens on rat gastrointestinal glutathione S-transferase theta 1-1 levels.

  Carcinogenesis 19981101

• Oltipraz stimulates the transcription of the manganese superoxide dismutase gene in rat hepatocytes.

  Carcinogenesis 19971101

• Mechanism of action of dietary chemoprotective agents in rat liver: induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism.

  Carcinogenesis 19970901

• Enhancement of radiation-inducible hepatic glutathione-S-transferases Ya, Yb1, Yb2, Yc1, and Yc2 gene expression by oltipraz: possible role in radioprotection.

  Molecular pharmacology 19970201

• Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention.

  Cancer research 19960515

• Inhibition of human immunodeficiency virus type 1 long terminal repeat-driven transcription by an in vivo metabolite of oltipraz: implications for antiretroviral therapy.

  Biochemical and biophysical research communications 19960425

• Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct.

  Archives of biochemistry and biophysics 19951201

• Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.

  Molecular pharmacology 19950701

• Cloning of cDNAs from fetal rat liver encoding glutathione S-transferase Yc polypeptides. The Yc2 subunit is expressed in adult rat liver resistant to the hepatocarcinogen aflatoxin B1.

  The Journal of biological chemistry 19940812

• Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.

  Proceedings of the National Academy of Sciences of the United States of America 19930501

• Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity.

  Hepatology (Baltimore, Md.) 19830101